Repligen is positioned as a core beneficiary of biopharma reshoring trends, with over 20% order growth and expanding Edge manufacturing footprint. The company targets attractive markets including monoclonal antibodies (8-10% market growth) and is moving into cell and gene therapies (over 30% market growth).
Cyborg Score Rationale
The company demonstrated strong momentum with 21.9% year-over-year revenue growth in Q3 2025, supported by innovation in next-generation bioprocessing modalities. However, recent stock volatility and modest profitability margins reflect near-term market uncertainty.
Top Insights
Launched three new high-performance chromatography resins (Dec 2025) targeting viral vectors and gene therapy applications
Over 20% order growth with expanding Edge manufacturing footprint positioning as reshoring beneficiary
Operates in high-growth end markets with cell/gene therapies growing at over 30% annually
Diversified product portfolio across Filtration, Chromatography, Process Analytics, and Proteins with manufacturing sites across US and Europe
Named Competitors
Cytiva — Bioprocessing and life science tools and services
Sartorius — Bioprocess solutions and lab instruments
Avantor — Life sciences products and services
Recent Developments
(February 2026) Q4 2025 earnings and full-year results reporting scheduled for February 24
(January 2026) Presented company overview at J.P. Morgan Healthcare Conference